FDA Modernization Act, 1997. Available at: http:// www.fda.gov/cder/guidance/105-115. Accessed 7 January 1999.
Bergner M. Quality of life, health status, and clinical research. Med Care 1989; 27(Suppl): S148–S156.PubMed
Leidy NK. Using functional status to assess treatment outcomes. Chest 1994; 106(6): 1645–1646.PubMed
Cella DF, Tulsky DS. Measuring quality of life today: Methodological aspects. Oncology 1990; 5: 29–38.
Levine S, Croog S. What constitutes quality of life? A conceptualization of the dimensions of life quality in heal-thy populations and patients with cardiovascular disease. In: Wenger N, Mattson M, Furberg C, Elinson J (eds), Assessment of Quality of Life in Clinical Trials of Car-diovascular Therapies. Greenwich, CT: La Jacq, 1984: 46-58.
Patrick DL, Erickson P. Health Status and Health Policy: Allocating Resources to Health Care. New York: Oxford University Press, 1993.
Barofsky I, Sugarbaker PH. Cancer. In: Spilker B (ed), Quality of Life Assessments in Clinical Trials. New York: Raven Press, 1990: 419–440.
Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619–626.PubMedCrossRef
Schipper H, Clinch JJ, Olweny CL. Quality of life studies: Definitions and conceptual issues. In: Spilker B (ed), 898 Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996: 11–24.
Leplege A, Hunt S. The problem of quality of life in med-icine. JAMA 1997; 278: 47–50.PubMedCrossRef
Joyce CRB, O'Boyle CA, McGee H(eds), Individual Quality of Life: Approaches to Conceptualisation and Assessment. Amsterdam: Harwood Academic Publishers, 1999.
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA 1995; 273: 59–65.PubMed
Ware JE. Methodological considerations in the selection of health status assessment procedures. In: Wenger N, Matt-son M, Furberg C, Elinson J (eds), Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Greenwich, CT: La Jacq, 1984: 87–111.
Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health 1999; 2: 113–127.PubMedCrossRef
Guyatt GH, Feeny D, Patrick DL. Issues in quality of life measurement in clinical trials. Control Clin Trials 1991; 12: 81S–90S.PubMed
Shumaker SA, Berzon R. The International Assessment of Health-Related Quality of Life: Theory, Translation, Measurement, and Analysis. Oxford: Rapid Communica-tions, 1995.
Revicki DA. Health care technology assessment and health-related quality of life. In: Banta D, Luce BR (eds), Health Care Technology and its Assessment: An International Perspective. New York: Oxford University Press, 1993: 114–131.
Gantz PA. Quality of life and the patient with cancer: In-dividual and policy implications. Cancer 1994; 74: 1445–1452.
Revicki DA, Ehreth JL. Health-related quality of life as-sessment and planning for the pharmaceutical industry. Clin Ther 1997; 19: 1101–1115.PubMedCrossRef
Spilker B (ed), Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996.
Staquet M, Hays R, Fayers P (eds), Quality of Life As-sessment in Clinical Trials. New York: Oxford University Press, 1998.
McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires, 2nd edn. New York: Oxford University Press, 1996.
Berzon RA, Donnelly MA, Simpson RL, Simeon GP, Til-son HH. Quality of life bibliography and indexes. Qual Life Res 1994; 6: 547–568.
McHorney CA. Generic health measurement: Past accom-plishments and a measurement paradigm for the 21st century. Ann Intern Med 1997; 127: 743–750.PubMed
Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. New York: McGraw-Hill, 1994.
American Psychological Association. Standard for Educa-tional and Psychological Tests. Washington, DC: American Psychological Association, 1985.
Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: What are the necessary measurement properties? J Clin Epidemiol 1992; 45: 1341-1345.PubMed
Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality of life and health status instruments: Development of scientific review criteria. Clin Ther 1996; 18: 979–992.PubMed
Hays R, Anderson R, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: Staquet M, Hays R, Fayers P (eds), Quality of Life Assessment in Clinical Trials. New York: Oxford University Press, 1998: 169–182.
Cronbach LJ, Meehl PE. Construct validity in psycholog-ical tests. Psychol Bull 1955; 52: 281-302.PubMed
Stewart AL, Hays RD, Ware JE. Methods of validating MOS health measures. In: Stewart AL, Ware JE (eds), Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham: Duke University Press, 1992: 309–324.
Hadorn DC, Hays RD. Multitrait-multimethod analysis of health-related quality of life preferences. Med Care 1991; 29: 829–840.PubMed
Hays R, Hadorn D. Responsiveness to change: An aspect of validity, not a separate dimension. Qual Life Res 1992; 1: 73–75.PubMed
Guyatt GH, Walter S, Norman G. Measuring change over time: Assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 171–178.PubMed
Kazdin AE. The meaning and measurement of clinical significance. J Consult Clin Psychol 1999; 67: 332-339.PubMed
Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–144.PubMed
Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2: 221–226.PubMedCrossRef
Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press, 1977.
Kazis LE, Anderson JJ, Meenan RF. Effect sizes for in-terpreting changes in health status. Med Care 1989; 27(suppl): S178-S189.PubMed
Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important dif-ference. Control Clin Trials 1989; 10: 407–415.PubMedCrossRef
Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-speci®c quality of life questionnaire. J Clin Epidemiol 1994; 47: 81–87.PubMedCrossRef
Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual.Boston: The Health Institute, New England Medical Center, 199
King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996; 5: 555–567.PubMedCrossRef
Norman GR. Issues in the use of change scores in ran-domized trials. J Clin Epidemiol 1989; 42(11): 1097–1105.PubMedCrossRef
Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsive-ness to change: The lesson of Cronbach. J Clin Epidemiol 1997; 50(8): 869–879.PubMedCrossRef
Fischer D, Stewart AL, Bloch DA, Lorig K, Laurent D, Holman H. Capturing the patient's view of change as a clinical outcome measure. JAMA 1999; 282: 1157–1162.PubMedCrossRef
Wyrwich KM, Tierney WM, Wolinsky FD. Further evi-dence supporting an SEM-based criterion for identifying 899 meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 57: 861-873.
Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37: 469-478.PubMedCrossRef
Testa MA. Interpretation of quality-of-life outcomes: Is-sues that afect magnitude and meaning. Med Care 2000; 38(suppl 9): 166-174.
Revicki DA. Instrument Selection and Validation: How Much is Enough? Regulatory Issues in Health-Related Quality of Life Assessment. Washington, DC: PhRMA/ FDA Interactive Workshop, March 1999.
Meinhart C, Tonascia S. Clinical Trials Design, Conduct and Analysis. New York: Oxford University Press, 1986.
Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in clinical trials: Serious problems and challenges. Stat Med 1998; 17: 517-532.PubMed
Bonomi A, Legro M, Leidy NK, et al. Maximizing quality in quality of life outcomes research: A multi-faceted ap-proach for clinical trials. Paper presented at the Annual Conference of the International Society for Quality of Life Research, Baltimore MD, November 1998.
Little RJA. Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc 1995; 90: 1112-1121.CrossRef
Jennrich R, Schluchter M. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-820.PubMedCrossRef
Laird NM, Ware JH. Random-effects models for longitu-dinal data. Biometrics 1982; 38: 963-974.PubMedCrossRef
Fairclough DL, Peterson HF, Cella D, Bonomi P. Com-parison of several model-based methods for analyzing in-complete quality of life data in cancer clinical trials. Stat Med 1998; 17: 781-796.PubMed
Hedeker D, Gibbons RD. Application of random-efects pattern-mixture models for missing data in longitudinal studies. Psych Methods 1997; 2: 64-78.
Revicki DA, Gold K, Buckman D, Chan K, Kallich JD, Woolley M. Imputing physical function scores missing owing to mortality: Results of a simulation comparing multiple techniques. Med Care (in press).
Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997; 16: 1197-1209.PubMedCrossRef
Zhang J, Quan H, Ng J, Stepanavage ME. Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 1997; 18: 204-221.PubMed
O'Brien PC. Procedures for comparing samples with mul-tiple endpoints. Biometrics 1984; 40: 511-521.CrossRef
Revicki DA, Moyle G, Stellbrink HJ, Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, squ-inavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 counts between 50 and 350 cells per cubic millimeter. AIDS 1999; 13: 851-858.PubMedCrossRef
Wu AW, Gray SM, Brookmeyer R. Application of random efects models and other methods to the analysis of multi-dimensional quality of life data in AIDS clinical trials. Med Care 1999; 37: 249-258.PubMed
Burke L. Regulatory Issues in the Use of Patient Reported Outcomes in Drug Labeling and Advertising. Presented at the Health-Related Quality of Life Workshop, Center for Drug Evaluation and Research, Food and Drug Adminis-tration, Rockville, MD, September 28, 2000.
Bukstein DA. Incorporating quality of life data into man-aged care formulary decisions: A case study with salme-terol. Am J Man Care 1997; 3: 1701-1706.